Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| 10528 | ETCTN | A Phase 1 Study of the Polymerase Theta (POLθ) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10538 | ETCTN | Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 trial | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10546 | ETCTN | Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10551 | ETCTN | A Phase 1/1b Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in Patients with BRCA1/2-mutant Tumors | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10553 | ETCTN | A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10554 | ETCTN | Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10556 | ETCTN | Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10558 | ETCTN | A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10559 | ETCTN | A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10561 | ETCTN | Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab | Adult CIRB - Early Phase Emphasis | Available to Open |